Abstract 292P
Background
Cervical cancer is the second most common malignancy among women in poor countries, according to the World Health Organization. According to some writers, cervical cancer is the second- or third-leading cause of mortality for women over 30 in Uzbekistan. Statistics on cervical cancer are hotly debated because not all women visit a doctor. On the pathologist's table, the diagnosis is frequently made.
Methods
During a regular checkup, 92 women between the ages of 25 and 48 were seen at the antenatal clinic of hospital No. 1g. Using liquid cytology and Pap test technologies, a screening cytological examination was performed on all women. According to clinical recommendations, the PAP test classes were interpreted as follows: class 1 — normal; class 2 — inflammatory type; class 3 — dyskaryosis; class 4 — cells suggestive for cancer or carcinoma; and class 5 — malignancy.
Results
50 women had normal cytological screening results from Pap tests, while 36 had inflammatory type outcomes. There was an inadequate type of sample in 6 women. A negative result of cytological screening by liquid cytology was found in 44 women; 36 women had cytograms that were within the normal range; and 10 women had atypical cells of stratified squamous epithelium that were of unknown significance. Additionally, 2 women developed epithelial squamous lesions of low severity. Compared to liquid cytology, which had a sensitivity of 77.0%, the Pap test had a sensitivity of 33.0%. While liquid cytology had a specificity of 72.0%, the Pap test had a higher specificity of 87.0%. Liquid cytology and the predictive value of a positive Pap test were comparable. Compared to the PAP test, the liquid cytology test had a better predictive value for a negative outcome.
Conclusions
The study's findings revealed that both approaches to early cervical cancer diagnosis estimate the incidence of the condition equally. In addition, liquid cytology makes it more probable to produce a positive result in the group of patients who actually have the disease and, to a lesser extent, in those who do not. When employing the liquid cytology method, the prognosis of the likelihood of the disease being absent in patients with a negative result was higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract